EP 2124968 A4 20131023 - COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE WASTING
Title (en)
COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE WASTING
Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON MUSKELSCHWUND
Title (fr)
COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'ATROPHIE MUSCULAIRE
Publication
Application
Priority
US 2006025657 W 20060630
Abstract (en)
[origin: WO2008005002A1] The invention provides compositions of oligonucleotides targeted at genes involved in muscle wasting and/or muscle growth. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the treatment of muscle wasting conditions and/or the promotion of muscle growth.
IPC 8 full level
A61K 31/70 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 5/00 (2006.01); C12Q 1/68 (2006.01)
CPC (source: EP)
A61K 31/70 (2013.01); A61P 21/00 (2017.12); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12N 2310/32 (2013.01)
Citation (search report)
- [X] CN 1718194 A 20060111 - OLIGOS ETC INC [US]
- [A] WO 03006478 A1 20030123 - OLIGOS ETC INC [US], et al
- [Y] US 2003129171 A1 20030710 - GROBET LUC [BE], et al
- [A] US 2005124566 A1 20050609 - ROBIN HOWARD [US], et al
- [E] WO 2006086667 A2 20060817 - AVI BIO PHARMA INC [US], et al
- [Y] ALEX CLOP ET AL: "A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep", NATURE GENETICS, vol. 38, no. 7, 4 June 2006 (2006-06-04), pages 813 - 818, XP055078053, ISSN: 1061-4036, DOI: 10.1038/ng1810 & ALEX CLOP: "Supplementary Figure 5", NATURE GENETICS, 4 June 2006 (2006-06-04), pages 1 - 3, XP055078055, Retrieved from the Internet <URL:http://www.nature.com/ng/journal/v38/n7/extref/ng1810-S5.pdf> [retrieved on 20130906]
- [Y] ACOSTA J ET AL: "Myostatin gene silenced by RNAi show a zebrafish giant phenotype", JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 119, no. 4, 10 October 2005 (2005-10-10), pages 324 - 331, XP027663478, ISSN: 0168-1656, [retrieved on 20051010]
- [A] THOMAS R. MAGEE ET AL: "Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass", THE JOURNAL OF GENE MEDICINE, vol. 8, no. 9, 29 June 2006 (2006-06-29), pages 1171 - 1181, XP055078809, ISSN: 1099-498X, DOI: 10.1002/jgm.946
- [A] DUMONCEAUX ET AL: "Improvement of Muscle Mass Using shRNA Targeting Myostatin or Activin Receptor IIb", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 13, 1 January 2006 (2006-01-01), pages S14, XP005675138, ISSN: 1525-0016
- [A] ZADOR E ET AL: "Antisense inhibition of myoD expression in regenerating rat soleus muscle is followed by an increase in the mRNA levels of myoD, myf-5 and myogenin and by a retarded regeneration", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1590, no. 1-3, 12 June 2002 (2002-06-12), pages 52 - 63, XP004362110, ISSN: 0167-4889, DOI: 10.1016/S0167-4889(02)00198-2
- [Y] PANTOPOULOS K ET AL: "The role of the 5' untranslated region of eukaryotic messenger RNAs in translation and its investigation using antisense technologies", PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, ACADEMIC PRESS, US, vol. 48, 1 January 1994 (1994-01-01), pages 181 - 238, XP009172334, ISSN: 0079-6603
- See references of WO 2008005002A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2008005002 A1 20080110; AU 2006345724 A1 20080110; AU 2006345724 B2 20131121; CA 2558160 A1 20071230; CA 2558160 C 20170103; EP 2124968 A1 20091202; EP 2124968 A4 20131023
DOCDB simple family (application)
US 2006025657 W 20060630; AU 2006345724 A 20060630; CA 2558160 A 20060630; EP 06774377 A 20060630